WHO stresses urgent need for R&D for drug-resistant TB alongside newly-prioritized antibiotic-resistant pathogens

28 FEBRUARY 2017 | GENEVA - WHO reaffirms the critical need for research and development (R&D) of new antibiotics to tackle the threat of drug-resistant tuberculosis (TB).

"Addressing drug-resistant TB research is a top priority for WHO and for the world," said Dr Margaret Chan, WHO Director-General. "More than US$ 800 million per year is currently necessary to fund badly needed research into new antibiotics to treat TB."

The MDR-TB public health crisis continues: there were an estimated 580 000 cases and 250 000 related deaths in 2015. Only 125 000 were started on treatment, and just half of those people were cured.

Only two new antibiotics to address MDR-TB have completed Phase IIB trials in the past 50 years. Both are still in Phase III trials, and more funding will be required to complete the process and to develop other effective treatment regimens.

On 27 February, WHO published a list of antibiotic-resistant pathogens that have recently been prioritized as posing great risk to human health.

"Mycobacterium tuberculosis, the bacterium responsible for human TB, was not included in the scope of the prioritization exercise as the intention was to identify previously unrecognised health threats due to increasing antibiotic resistance. There is already consensus that TB is a top priority for R&D for new antibiotics," said Dr Marie-Paule Kieny, Assistant Director-General at WHO... 

More News
9 Aug 2017
The United States Food and Drug Administration held a public workshop regarding scientific and clinical trial design considerations for development of new tuberculosis drug regimens. This public workshop was intended to provide information for and gain perspective pertaining to development efforts...
4 May 2017
Spero Therapeutics Receives Grant from National Institutes of Health to Explore Novel Treatment Combinations for Tuberculosis CAMBRIDGE, Mass., May 4, 2017—Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, today...
11 Apr 2017
Scientist at Rutgers University and their collaborators have published an article in Molecular Cell illustrating the three-dimensional structure of the drug target for the drug rifampicin. The abstract for the article is below. TITLE: Structural Basis of Mycobacterium tuberculosis Transcription and...